Neurotrophic factor signaling represents a promising therapeutic approach for Parkinson's disease (PD) by promoting dopaminergic neuron survival, function, and potential regeneration. The Glial Cell Line-Derived Neurotrophic Factor (GDNF) family and its receptors have been extensively studied as disease-modifying targets for PD [[PMID:23535953]].
The GDNF family ligands (GFLs) are essential for the development, maintenance, and survival of dopaminergic neurons. This mechanism page explores the molecular signaling pathways, genetic associations, and clinical trial evidence for neurotrophic factor-based therapies in PD.
GDNF was first discovered in 1973 as a potent survival factor for dopaminergic neurons [[PMID:8215717]]. It is the most studied neurotrophic factor for PD therapy.
| Property | Description |
|---|---|
| Gene | GDNF (8p21.2) |
| Protein size | 134 amino acids (mature), 211 amino acids (prepro) |
| Molecular weight | ~15 kDa (mature dimer) |
| Primary receptor | GFRα1/RET complex |
| Tissue expression | Highest in striatum, substantia nigra, spinal cord |
| Key functions | Dopaminergic neuron survival, neurite outgrowth, synaptic function |
GDNF signals through a unique two-component receptor system. The glycosylphosphatidylinositol (GPI)-anchored GFRα receptor recruits GDNF, then the complex binds to the RET receptor tyrosine kinase, triggering downstream signaling cascades [[PMID:10441138]].
Neurturin is a GDNF family member that also signals through GFRα2/RET, with particularly high expression in the nervous system [[PMID:9183748]].
| Property | Description |
|---|---|
| Gene | NRTN (19p13.3) |
| Protein size | 103 amino acids (mature) |
| Primary receptor | GFRα2/RET complex |
| Tissue expression | Peripheral nervous system, CNS |
| Key functions | Motor neuron survival, enteric nervous system development |
Artemin signals through GFRα3/RET and is involved in sensory and autonomic neuron survival [[PMID:10559223]].
Persephin signals through GFRα4/RET and has neuroprotective effects on dopaminergic and motor neurons [[PMID:10612841]].
| Receptor | Gene | Primary Ligand | Alternative Ligands | Expression Pattern |
|---|---|---|---|---|
| GFRα1 | GFRA1 | GDNF | NRTN, ARTN | Dopaminergic regions, striatum |
| GFRα2 | GFRA2 | NRTN | GDNF | Enteric nervous system, PNS |
| GFRα3 | GFRA3 | ARTN | — | Sensory, autonomic neurons |
| GFRα4 | GFRA4 | PSPN | — | Thyroid, pituitary |
GFRα1 is the primary receptor mediating GDNF signaling in dopaminergic neurons. Key features include [[PMID:14550789]]:
The RET (REarranged during Transfection) receptor is a cadherin family receptor tyrosine kinase [[PMID:14739320]]:
| Property | Description |
|---|---|
| Gene | RET (10q11.21) |
| Protein size | 1114 amino acids (full-length) |
| Domains | Cadherin-like, cysteine-rich, tyrosine kinase |
| Isoforms | RET9, RET51 (alternative splicing) |
| Expression | CNS (dopaminergic neurons), PNS, endocrine |
Once activated by GFL-GFRα complex, RET triggers multiple downstream signaling cascades [[PMID:22983484]]:
The PI3K-Akt pathway is the primary mediator of GDNF-induced neuronal survival [[PMID:15694268]]:
The MAPK pathway mediates neurite outgrowth and differentiation [[PMID:15834421]]:
The PLC-γ pathway increases intracellular calcium and modulates synaptic transmission [[PMID:17904221]]:
| Pathway | Primary Outcome | Key Mediators |
|---|---|---|
| PI3K-Akt | Neuronal survival | Akt, mTOR, BAD, FoxO |
| MAPK/ERK | Neurite outgrowth | Ras-Raf-MEK-ERK, CREB |
| PLC-γ | Synaptic plasticity | PLC-γ, Ca²⁺, PKC |
| JNK | Stress response | JNK, c-Jun (context-dependent) |
The RET gene has been associated with PD risk in multiple genome-wide association studies (GWAS) [[PMID:22678054]]:
GFRA1 variants modify PD susceptibility and progression [[PMID:28745395]]:
Neurotrophic factor signaling interacts with other PD risk genes [[PMID:31148597]]:
| Gene Interaction | Effect |
|---|---|
| GDNF + LRRK2 | Synergistic neuroprotection |
| GBA + GDNF | GCase affects GDNF processing |
| PARK2 (Parkin) + GDNF | Impaired retrograde signaling |
| SNCA + GDNF | α-synuclein aggregation interferes with RET trafficking |
Post-mortem studies show decreased GDNF levels in PD substantia nigra [[PMID:11891914]]:
α-Synuclein pathology impairs RET signaling [[PMID:24792388]]:
Oxidative stress in PD disrupts neurotrophic signaling [[PMID:21920360]]:
Microglial activation affects neurotrophic factor signaling [[PMID:25959775]]:
CERE-120 was the first gene therapy trial using neurotrophic factors for PD [[PMID:17512964]].
| Trial Phase | Participants | Delivery | Results |
|---|---|---|---|
| Phase 1 (2005) | 12 | AAV2-NRTN to putamen | Safe, some improvement |
| Phase 2 (2008) | 58 | AAV2-NRTN vs sham | No significant benefit |
| Open-label extension | — | — | Gradual decline |
Key findings:
Multiple trials have tested AAV-GDNF delivery [[PMID:28333565]]:
| Trial | Status | Key Findings |
|---|---|---|
| Voyager Therapeutics | Phase 1-2 | Dose-escalation completed |
| Roche/Genentech | Phase 1 | Stopped for business reasons |
| Prevail Therapeutics | Preclinical | Strong efficacy in models |
Mechanism of AAV-GDNF:
bfe67bb53c3c532ef4237fa3323691ae27404769
Preclinical studies show synergistic effects [[PMID:31148597]]:
bfe67bb53c3c532ef4237fa3323691ae27404769
Potential synergies between neurotrophic and lysosomal therapies [[PMID:32893341]]:
bfe67bb53c3c532ef4237fa3323691ae27404769
Rationale for combination therapy [[PMID:24792388]]:
bfe67bb53c3c532ef4237fa3323691ae27404769
Neurotrophic factor signaling through the GDNF family and RET receptor represents a compelling disease-modifying approach for Parkinson's disease. The signaling network involving GFRα1-RET, PI3K-Akt, MAPK/ERK, and PLC-γ pathways provides robust pro-survival and regenerative signals to dopaminergic neurons.
Despite promising preclinical data, clinical translation has been challenging due to delivery issues, patient selection, and the complexity of PD pathogenesis. Recent advances in gene therapy vectors, combination approaches targeting multiple pathways, and improved patient stratification are renewing interest in this therapeutic strategy.
Key takeaways:
bfe67bb53c3c532ef4237fa3323691ae27404769